By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market Wednesday that its third-quarter revenues increased 87 percent year over year.

The Omaha, Neb.-based pharmacogenomics and molecular diagnostics firm reported total revenues of $8.3 million for the three-month period ended Sept. 30, compared to $4.4 million for the third quarter of 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.